

- **Name:** Margaret Ann Shipp
- **Current Position & Affiliation:** Professor of Medicine, Harvard Medical School
- **Country:** USA

• **Educational Background:**

INSTITUTION AND LOCATION	DEGREE (if applicable)	Completion Date MM/YYYY	FIELD OF STUDY
Southern Methodist University	B.A.	05/1975	English and Biology
Washington University School of Medicine	M.D.	05/1979	Medicine

• **Professional Experience:**

- 2019 – Present: Editorial Board, *Blood Cancer Discovery*
- 2017 – 2019: Scientific Advisory Board, Memorial Sloan Kettering Cancer Center Lymphoma SPORE, New York, NY
- 2017 – Present: Scientific Advisory Board, Mayo-Iowa Lymphoma SPORE, Rochester, MN
- 2017 – Present: Scientific Advisory Board, Lymphoma Research Foundation, New York, NY
- 2016 – Present: Director, Lymphoma Research Center, Dana-Farber Cancer Institute (DFCI), Boston, MA
- 2013 – Present: Associate Member, Broad Institute, Cambridge, MA
- 2012 – 2016: Councilor, American Society of Hematology, Washington, DC
- 2011 – Present: Editorial Board, *Cancer Discovery*
- 2010 – Present: Chief, Division of Hematologic Neoplasia, DFCI, Boston, MA
- 2009 – Present: Steering Committee, International Symposium on Hodgkin Lymphoma, Cologne, Germany
- 2008 – 2011: Board of Directors, American Association for Cancer Research, Philadelphia, PA
- 2007 – Present: Professor, Harvard Medical School (HMS); DFCI, Boston, MA
- 2002 – 2012: Editorial Board, *Blood*
- 2001 – 2007: Scientific Advisory Board, Lymphoma Research Foundation, New York, NY
- 1999 – 2021: Scientific Advisory Committee, International Conference on Malignant Lymphoma, Lugano, Switzerland
- 1999 – 2020: Director, Lymphoma Program, Dana-Farber/Harvard Comprehensive Cancer Center, Boston, MA
- 1999 – 2010: Medical and Scientific Affairs Committee, Leukemia and Lymphoma Society of America, Rye Brook, NY
- 1997 – Present: Attending Physician Bone Marrow Transplant Service, DFCI/BWH, Boston, MA
- 1996 – 1999: Chairperson, National Cancer Center Network, Lymphoma Committee, Plymouth Meeting, PA
- 1994 – 2007: Associate Professor of Medicine, HMS; DFCI, Boston, MA
- 1988 – Present: Attending Physician, Medical Oncology, DFCI, Boston, MA
- 1988 – 1994: Assistant Professor of Medicine, HMS; DFCI, Boston, MA
- 1986 – Present: Associate Physician, Medicine, Brigham and Women’s Hospital, Boston, MA

15th Annual Meeting of the Korean Society of Medical Oncology & 2022 International Conference

- 1986 – 1988: Instructor in Medicine, HMS; DFCI, Boston, MA
- 1983 – 1986: Fellow in Medical Oncology, HMS; DFCI, Boston, MA
- 1982 – 1983: Research Fellow in Immunology, Washington University School of Medicine, St. Louis, MO
- 1979 – 1982: Intern and Resident in Internal Medicine, Barnes Hospital, St. Louis, MO

- Professional Organizations:

- Main Scientific Publications:

1. Roemer M, Advani RH, Ligon AH, Natkunam Y, Redd RA, Homer H, Connelly CF, Sun HH, Daadi SE, Freeman GJ, Armand P, Chapuy B, de Jong D, Hoppe RT, Neuberger DS, Rodig SJ, Shipp MA. *PD-L1 and PD-L2 Genetic Alterations Define Classical Hodgkin Lymphoma and Predict Outcome*. Selected as “Rapid Communication” (top 5% of JCO published papers). *J Clin Oncol*. 2016;34(23):2690-7. PMID: 27069084.
2. Roemer MGM, Redd RA, Cader FZ, Pak CJ, Abdelrahman S, Ouyang J, Sasse S, Younes A, Fanale M, Santoro A, Zinzani PL, Timmerman J, Collins GP, Ramchandren R, Cohen JB, De Boer JP, Kuruvilla J, Savage KJ, Trneny M, Ansell S, Kato K, Farsaci B, Sumbul A, Armand P, Neuberger DS, Pinkus GS, Ligon AH, Rodig SJ, Shipp MA. Major Histocompatibility Complex Class II and Programmed Death Ligand 1 Expression Predict Outcome Following Programmed Death 1 Blockade in Hodgkin Lymphoma. Selected as “Rapid Communication” (top 5% of JCO published papers). *J Clin Oncol*. 2018; 36(10):942-950. PMID: 29394125.
3. Wienand K*, Chapuy B*, Stewart C*, Dunford AJ*, Wu D, Kim J, Kamburov A, Wood TR, Cader FZ, Ducar MD, Thorner AR, Nag A, Heubeck AT, Buonopane MJ, Redd RA, Bojarczuk K, Lawton LN, Armand P, Rodig SJ, Fromm JR**, Getz G**, Shipp MA**. Genomic Analyses of Flow-sorted Hodgkin Reed Sternberg Cells Reveal Complementary Mechanisms of Immune Evasion. *Blood Advances*. 2019; 3(23): 4066-4080. PMID: 31816062. *contributed equally, **supervised jointly.
4. Chapuy B*, Stewart C*, Dunford AJ*, Kim J, Wienand K, Kamburov A, Griffin GK, Chen PH, Lako A, Redd RA, Cote CM, Ducar MD, Thorner AR, Rodig SJ, Getz G**, Shipp MA**. Genomic Analyses of Primary Mediastinal Large B-cell Lymphoma Reveal New Drivers and Mechanisms of Sensitivity to PD-1 Blockade. *Blood*. 2019; 134(26): 2360-2382. PMID: 31697821. *contributed equally, **supervised jointly.